ADMA · ADMA Biologics Inc
$11.06
+3.60% last session
End-of-day data · close of 2026-10-26
Market cap
$2B
Enterprise value
$3B
Trailing P/E
15.8
Forward P/E
11.7
Dividend yield
0.0%
Beta
0.69
Avg volume
3M
Employees
1K
Daily Change %
3.60%
5 Days Change
1.05%
10 Days Change
3.60%
30 Days Change
17.96%
60 Days Change
18.47%
Month to Day Change
11.43%
Year to Day Change
-39.34%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — ADMA
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-07-15
Latest call per bank · past 12 months
Recent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-07-15 | Mizuho | Maintains | Outperform | $20.00 → $17.00 |
| 2026-05-07 | Canaccord Genuity | Maintains | Buy | $21.00 → $18.00 |
| 2026-05-07 | Mizuho | Maintains | Outperform | $24.00 → $20.00 |
| 2026-04-21 | Canaccord Genuity | Initiates | Buy | $0.00 → $21.00 |
| 2026-04-13 | Mizuho | Maintains | Outperform | $30.00 → $24.00 |
| 2026-03-26 | Cantor Fitzgerald | Downgrade | Overweight → Neutral | $0.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-26
- neutral: RSI (14): RSI is 64 — neutral momentum, neither overbought nor oversold.
- bullish: Price vs 50-day MA: Trading 12.2% above the 50-day MA ($9.86).
- bearish: Price vs 200-day MA: Trading 0.2% below the 200-day MA ($11.09).
- bearish: MA cross: The 50-day MA sits below the 200-day MA (death-cross regime) — the longer-term trend points down.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.03) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($7.60) and high ($20.38).
ADMA Price Chart
Loading chart for ADMA…
Fundamentals
About ADMA Biologics Inc
ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company operates through ADMA BioManufacturing and Plasma Collection Centers segments. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, a human polyclonal antibody product for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics comprising products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company sells its products through independent distributors, drug wholesalers, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was incorporated in 2004 and is headquartered in Ramsey, New Jersey.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$131B 14.1% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$83B 5.0% YTD
MRNA
Moderna, Inc.
$79B 574.3% YTD
ARGX
argenx SE
$55B 3.4% YTD
ONC
BeOne Medicines Ltd.
$42B 22.1% YTD
RVMD
Revolution Medicines, Inc.
$39B 130.9% YTD
RPRX
Royalty Pharma plc
$37B 69.9% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$30B -42.8% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.